Now showing items 1-2 of 2

    • Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial 

      Felker, G. Michael; Solomon, Scott D.; Claggett, Brian; Díaz, Rafael; McMurray, John J.V.; Metra, Marco; Anad, Inder; Crespo-Leiro, María Generosa; Dahlström, Ulf; Goncalvesova, Eva; Howlett, Jonathan G.; MacDonald, Peter; Parkhomenko, Alexander; Tomcsányi, János; Abbasi, Siddique A.; Heitner, Stephen B.; Hucko, Thomas; Kupfer, Stuart; Malik, Fady I.; Teerlink, John R. (American Medical Association, 2021-10-13)
      [Abstract] Importance: Heart failure with reduced ejection fraction is a progressive clinical syndrome, and many patients' condition worsen over time despite treatment. Patients with more severe disease are often intolerant ...
    • Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial 

      Pabon, Maria; Cunningham, Jon; Claggett, Brian; Felker, Michael; McMurray, John J.V.; Metra, Marco; Díaz, Rafael; Wang, Xiaowen; Arias-Mendoza, Alexandra; Bonderman, Diana; Crespo-Leiro, María Generosa; Fonseca, Cândida; Goncalvesova, Eva; Lund, Mayanna; O’Meara, Eileen; Sliwa-Hahnle, Karen; Malik, Fady I.; Solomon, Scott D.; Teerlink, John R. (Elsevier on behalf of the American College of Cardiology Foundation, 2023-10-11)
      [Abstract] Background: Women with heart failure with reduced ejection fraction (HFrEF) receive less guideline-recommended therapy and experience worse quality of life than men. Objectives: The authors sought to assess ...